mva-hbv
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 28, 2019 (NCT03866187)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05343481 | Phase 2 | Sep 21, 2022 | Barinthus Biopharmaceuticals |
| NCT04778904 | Phase 1/Phase 2 (Phase 2) | Dec 22, 2020 | Barinthus Biopharmaceuticals |
| NCT03866187 | Phase 1 | Mar 28, 2019 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Barinthus Biopharmaceuticals | For profit | 2 | 2 | 1 | 2020 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1